FMP
Millendo Therapeutics, Inc.
MLND
NASDAQ
Inactive Equity
Millendo Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing novel treatments for orphan endocrine diseases in the United States. Its lead product candidates include livoletide, a potential treatment for Prader-Willi syndrome; nevanimibe, a potential treatment for patients with classic congenital adrenal hyperplasia; and MLE-301, a neurokinin 3-receptor antagonist for the treatment of vasomotor symptoms in menopausal women. The company is headquartered in Ann Arbor, Michigan.
1.06 USD
-0.06000006 (-5.66%)
Free Cash Flow
Year
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
Revenue
-
-
-
-
-
-
-
-
-
-
Revenue %
-
-
-
-
-
-
-
-
-
Operating Cash Flow
-1.35M
-2.8M
-1.99M
-3.7M
-4.22M
-
-
-
-
-
Operating Cash Flow %
100
100
100
100
100
100
100
100
100
Cap Ex
-
-
-1.8k
-149.78k
-
-
-
-
-
-
Cap Ex %
100
100
100
100
100
-
-
-
-
Free Cash Flow
-1.35M
-2.8M
-2M
-3.85M
-4.22M
-
-
-
-
-
Weighted Average Cost Of Capital
Price
0.3
Beta
Diluted Shares Outstanding
4.9M
Costof Debt
4.15
Tax Rate
After Tax Cost Of Debt
4.15
Risk Free Rate
Market Risk Premium
Cost Of Equity
Total Debt
0
Total Equity
1.47M
Total Capital
1.47M
Debt Weighting
0
Equity Weighting
100
Wacc
5.8
Build Up Free Cash Flow
Year
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
Revenue
-
-
-
-
-
-
-
-
-
-
Operating Cash Flow
-1.35M
-2.8M
-1.99M
-3.7M
-4.22M
-
-
-
-
-
Cap Ex
-
-
-1.8k
-149.78k
-
-
-
-
-
-
Free Cash Flow
-1.35M
-2.8M
-2M
-3.85M
-4.22M
-
-
-
-
-
Wacc
5.8
5.8
5.8
5.8
5.8
Pv Lfcf
-
-
-
-
-
Sum Pv Lfcf
-
Terminal Value
Growth In Perpetuity Method
Long Term Growth Rate
Wacc
5.8
Free Cash Flow T1
0
Terminal Value
0
Present Terminal Value
0
Intrinsic Value
Enterprise Value
0
Net Debt
-1.84M
Equity Value
1.84M
Diluted Shares Outstanding
4.9M
Equity Value Per Share
0.38
Projected DCF
0.3752 0.2%
